Log In
Print
BCIQ
Print
Print this Print this
 

Relday, risperidone

  Manage Alerts
Collapse Summary General Information
Company Durect Corp.
DescriptionSubcutaneous drug delivery system plus a subcutaneous once-monthly formulation of risperidone formulated using Durect's SABER controlled-release technology
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationSchizophrenia
Indication DetailsTreat schizophrenia
Regulatory Designation

Partner

Zogenix Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today